Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing.
Transfusion
; 61(4): 1181-1190, 2021 04.
Article
in English
| MEDLINE | ID: covidwho-1045671
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
BACKGROUND:
The efficacy of convalescent plasma (CP), an alternative for the treatment of COVID-19, depends on high titers of neutralizing antibodies (nAbs), but assays for quantifying nAbs are not widely available. Our goal was to develop a strategy to predict high titers of nAbs based on the results of anti-SARS-CoV-2 immunoassays and the clinical characteristics of CP donors. STUDY DESIGN ANDMETHODS:
A total of 214 CP donors were enrolled and tested for the presence of anti-SARS-CoV-2 antibodies (IgG) using two commercial immunoassays EUROIMMUN (ELISA) and Abbott (Chemiluminescence). Quantification of nAbs was performed using the Cytopathic Effect-based Virus Neutralization test. Three criteria for identifying donors with nAbs ≥ 1160 were tested - C1 Curve ROC; - C2 Conditional decision tree considering only the IA results and - C3 Conditional decision tree including both the IA results and the clinical variables.RESULTS:
The performance of the immunoassays was similar referring to both S/CO and predictive value for identifying nAbs titers ≥1160. Regarding the studied criteria for identifying CP donors with high nAbs titers (a) C1 showed 76.1% accuracy if S/CO = 4.65, (b) C2 presented 76.1% accuracy if S/CO ≥4.57 and (c) C3 had 71.6% accuracy if S/CO was ≥4.57 or if S/CO was between 2.68-4.57 and the last COVID-19-related symptoms were recent (within 19 days).CONCLUSION:
SARS-CoV-2 IgG immunoassays (S/CO) can be used to predict high anti-SARS-CoV-2 nAbs titers. This study has proposed different criteria for identifying donors with ≥1160 nAbs titers, all with high efficacy.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Immunoglobulin G
/
Antibodies, Neutralizing
/
COVID-19 Serological Testing
/
COVID-19
/
Antibodies, Viral
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Transfusion
Year:
2021
Document Type:
Article
Affiliation country:
Trf.16268
Similar
MEDLINE
...
LILACS
LIS